- Home
- AUID vs RGLS Comparison
AUID vs RGLS Comparison
Compare AUID & RGLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUID
- RGLS
- Stock Information
- Founded
- AUID 2009
- RGLS 2007
- Country
- AUID United States
- RGLS United States
- Employees
- AUID N/A
- RGLS N/A
- Industry
- AUID Computer Software: Prepackaged Software
- RGLS Biotechnology: Pharmaceutical Preparations
- Sector
- AUID Technology
- RGLS Health Care
- Exchange
- AUID Nasdaq
- RGLS Nasdaq
- Market Cap
- AUID 88.5M
- RGLS 102.1M
- IPO Year
- AUID N/A
- RGLS 2012
- Fundamental
- Price
- AUID $6.20
- RGLS $1.32
- Analyst Decision
- AUID
- RGLS Strong Buy
- Analyst Count
- AUID 0
- RGLS 6
- Target Price
- AUID N/A
- RGLS $10.33
- AVG Volume (30 Days)
- AUID 27.5K
- RGLS 315.1K
- Earning Date
- AUID 11-07-2024
- RGLS 03-20-2025
- Dividend Yield
- AUID N/A
- RGLS N/A
- EPS Growth
- AUID N/A
- RGLS N/A
- EPS
- AUID N/A
- RGLS N/A
- Revenue
- AUID $758,638.00
- RGLS N/A
- Revenue This Year
- AUID N/A
- RGLS N/A
- Revenue Next Year
- AUID N/A
- RGLS N/A
- P/E Ratio
- AUID N/A
- RGLS N/A
- Revenue Growth
- AUID 97.40
- RGLS N/A
- 52 Week Low
- AUID $4.62
- RGLS $1.15
- 52 Week High
- AUID $13.63
- RGLS $3.79
- Technical
- Relative Strength Index (RSI)
- AUID 52.37
- RGLS 41.01
- Support Level
- AUID $5.26
- RGLS $1.24
- Resistance Level
- AUID $6.39
- RGLS $1.40
- Average True Range (ATR)
- AUID 0.39
- RGLS 0.11
- MACD
- AUID 0.06
- RGLS -0.02
- Stochastic Oscillator
- AUID 83.14
- RGLS 31.91
About AUID authID Inc.
AuthID Inc is a company engaged in ensuring cyber-savvy enterprises "Know Who's Behind the Device" for every customer or employee login and transaction. Through its easy-to-integrate, patented, biometric identity platform, authID quickly and accurately verifies a user's identity, eliminating any assumption of who is behind a device and preventing cybercriminals from taking over accounts. authID combines digital onboarding, biometric passwordless authentication and account recovery, with a fast, accurate, user-friendly experience-delivering identity verification.
About RGLS Regulus Therapeutics Inc.
Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. The product candidate of the company is RGLS8429, an anti-miR next-generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), and is in Phase 1b clinical development.